相关实验视频

Updated: Jan 6, 2026

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction

Published on: April 24, 2016

在以人口为基础的分析中,常规干预未能为早期主要唾液腺边缘区域淋巴瘤提供生存益处

Jiaqi Qin¹, Hailing Liu², Xiaojing Shi³

¹Department of Hematology, Suzhou Municipal Hospital, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215001, China.

Annals of hematology

|October 7, 2025

概括

这项研究发现,传统治疗不能改善早期主要唾液腺边缘区域淋巴瘤的存活率. 对新型治疗方法的进一步研究对于改善患者的治疗结果至关重要.

科学领域:

在瘤学瘤学.
血液学血液学血液学
流行病学流行病学

背景情况:

主要唾液腺边缘区域淋巴瘤 (MSGMZL) 是一种罕见的恶性瘤,通常在早期阶段被诊断出来 (I/II).
关于早期MSGMZL.L.的各种治疗方式的疗效,证据有限.
需要对长期结果进行全面分析,以指导临床实践.

研究的目的:

分析早期MSGMZL不同治疗方法的长期结果.
确定影响整体和疾病特异性生存的预后因素.
评估治疗时间和潜在的新策略的影响.

主要方法:

一项基于人口的队列研究,利用来自SEER数据库的1,091名早期MSGMZL患者 (1992-2016) 的数据.
统计分析包括单变量和多变量考克斯回归,倾向得分匹配 (PSM) 和分层分析.
随访时间中位数为81.0个月.

主要成果:

总生存时间的关键预后因素:年龄>60岁 (HR 5.99),在2005年之前诊断 (HR 1.46),并存的恶性瘤 (HR 1.61).
年龄>60岁 (HR 4.25) 和2005年之前的诊断 (HR 1.98) 对特定疾病的生存率产生了不利影响.
在传统干预措施中,PSM没有显示生存差异;在2005年后诊断的患者的生存率有所改善.

结论:

传统的治疗方法不会为早期的MSGMZL.L.提供生存优势.
诊断时的年龄和诊断年的年龄是显著的预后因素.
2005年后改善的生存率表明新型治疗策略的潜在好处,需要进一步研究.

关键词:

化疗化疗是一种化学疗法.主要的唾液腺是什么边缘区域的b细胞淋巴瘤预测因素预测因素辐射疗法辐射疗法手术手术手术术术

更多相关视频

Radiation Treatment of Organotypic Cultures from Submandibular and Parotid Salivary Glands Models Key In Vivo Characteristics

Radiation Treatment of Organotypic Cultures from Submandibular and Parotid Salivary Glands Models Key In Vivo Characteristics

Published on: May 17, 2019

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...